AHD International, Importer and Distributor of Nutraceutical Ingredients
Products

Anti-Oxidants & Immune Enhancing Ingredients

Cardiovascular Health

Ingredients for Healthy Joints and Cartilage

Memory & Mental Enhancing Ingredients

Menopause and Women's Health

Mood and Emotional Health

Weight Loss

All Natural Products

Product Infomation

Nutraceutical News
Clinical Studies

Resources

Links
Resources

What's Hot?
Collagen Bulk Sales
Hoodia Bulk Sales
Hyaluronic Acid
Who We Are
About AHD
Contact AHD

Gamma Linolenic Acid Clinical Study


Impact of early dietary gamma-linolenic acid supplementation on atopic eczema in infancy.

Kitz R, Rose MA, Schonborn H, Zielen S, Bohles HJ.

Department of Allergology and Pulmonology, Children's Hospital, Goethe University, Frankfurt, Germany.

Polyunsaturated fatty acids (PUFAs) are components of cell membranes and may play an immunomodulating role in the pathogenesis of atopic dermatitis (AD). The goal was to determine the impact of PUFAs on AD by dietary supplementation of infants. Based on the parents' decision on their babies' primary feeding, mothers and newborns were randomized to the supplementation with gamma-linolenic acid (GLA) or placebo for up to 6 months. Breastfed infants received GLA by supplementing their mothers. Formula diet was commercial whey hydrolysate unsupplemented with PUFAs. Of 131 eligible infants, 24 developed AD within the first year of life. Of these, nine belonged to the exclusively breastfed group (n = 58), 14 to the combined-fed group (n = 53), and one to the never breastfed group (n = 20). We could not find an influence of GLA on the development of AD. In subjects with AD, at 1 yr of age the serum-immunoglobulin E (IgE) was the lowest in the GLA-supplemented group A-subjects. In the GLA-supplemented group, GLA-levels in breast milk were similar in atopic and non-atopic infants. In the non-supplemented group the GLA-content of breast milk was 0.07% of total fatty acids in atopic infants vs. 0.17% in non-atopic infants (p < 0.01). Dietary GLA-supplementation could not prevent AD. Interestingly, the number of infants developing AD was the lowest in never breastfed children. In infants suffering from AD, GLA-supplementation seemed to reduce total IgE in the first year of life.

PMID: 16618360 [PubMed - in process]



<< Back to Gamma Linolenic Acid Clinical Study List


We are strictly a bulk supplier to manufacturers – we do not sell to re-sellers or individuals. Our minimum order size is approximately 25 kilos. We are one of only a few suppliers that carry $5 million product liability insurance for our customers. AHD International LLC is classified as a importer, exporter, manufacturer, distributor of nutritional ingredients depending on the ingredient specified. AHD has 5 warehouse locations across North America and sales agents in over 10 countries. We are the only ingredient company to be awarded the Dun and Bradstreet's fastest growing company in America twice in 1999 and 2002.

For quotes please click here

*"These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."



© AHD International, LLC.
Legal and Privacy Statement

Entrepeneur Hot 100

Named in Dun & Bradstreet Entrepreneur Magazine "Hot 100" fastest growing companies.
For Vendors

Get a Quote
Partner With Us

Choose AHD

AHD has over 650 customers.

5 North American warehouses making large quantity orders and quick delivery possible.

Representatives in USA, Mexico, Chile, Brazil and Uruguay.

AHD has a reputation for carrying the highest quality products in the industry.

Exclusivity of premium products from some of the top nutraceutical companies world. wide.

News

Industry News
Business News
Food & Beverage
Sports Nurtition